Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Berger

Showing results (81-90 of 123) with videos related to

Pageof 13
Sort By:
The Lancet Regional Health. Europe|November 25, 2022
Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort studySarah Wilson, Floriane Calocer, Fabien Rollot, et al.
JAMA Network Open|June 23, 2023
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple SclerosisEdouard Januel, David Hajage, Pierre Labauge, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 14, 2019
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MSCaroline Lavie, Fabien Rollot, Françoise Durand-Dubief, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 3, 2020
Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS studySandra Vukusic, Iuliana Ionescu, Catherine Cornu, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 22, 2024
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022Lina Jeantin, Edouard Januel, Pierre Labauge, et al.
JAMA Neurology|February 26, 2014
Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective studyMikael Cohen, Elisabeth Maillart, Ayman Tourbah, et al.
JAMA Neurology|February 12, 2024
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple SclerosisNail Benallegue, Fabien Rollot, Sandrine Wiertlewski, et al.
BMC Neurology|October 28, 2025
Influence of geographical accessibility to specialist and primary care givers on excess mortality of multiple sclerosis patients in FranceSarah Wilson, Emmanuelle Leray, Floriane Calocer, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 11, 2025
Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple SclerosisMarie Mainguy, Romain Casey, Sandra Vukusic, et al.
Neurology|January 31, 2016
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational studyLaetitia Barbin, Chloe Rousseau, Natacha Jousset, et al.
Pageof 13

Showing results (81-90 of 123) with videos related to

Sort By:
Pageof 13
The Lancet Regional Health. Europe|November 25, 2022
Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort studySarah Wilson, Floriane Calocer, Fabien Rollot, et al.
JAMA Network Open|June 23, 2023
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple SclerosisEdouard Januel, David Hajage, Pierre Labauge, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 14, 2019
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MSCaroline Lavie, Fabien Rollot, Françoise Durand-Dubief, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 3, 2020
Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS studySandra Vukusic, Iuliana Ionescu, Catherine Cornu, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 22, 2024
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022Lina Jeantin, Edouard Januel, Pierre Labauge, et al.
JAMA Neurology|February 26, 2014
Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective studyMikael Cohen, Elisabeth Maillart, Ayman Tourbah, et al.
JAMA Neurology|February 12, 2024
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple SclerosisNail Benallegue, Fabien Rollot, Sandrine Wiertlewski, et al.
BMC Neurology|October 28, 2025
Influence of geographical accessibility to specialist and primary care givers on excess mortality of multiple sclerosis patients in FranceSarah Wilson, Emmanuelle Leray, Floriane Calocer, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 11, 2025
Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple SclerosisMarie Mainguy, Romain Casey, Sandra Vukusic, et al.
Neurology|January 31, 2016
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational studyLaetitia Barbin, Chloe Rousseau, Natacha Jousset, et al.
Pageof 13